TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria
Brief Summary: The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and hypercholesterolaemia.


Options:
A: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Unikalk | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Unikalk; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Statin (simvastatin); Assigned to Arm(s): N/A
C: Arm Label: EZ/Simva 10/40 mg; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): EZ/Simva 10/40 mg | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Non-diabetic Patients With Moderate Proteinuria
Brief Summary: The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.


Options:
A: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A
B: Arm Label: ABT-335 plus rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335 plus rosuvastatin | Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: ABT-335 plus rosuvastatin; Assigned to Arm(s): ABT-335 plus rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Arm Label: standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard therapy | Arm Label: fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): fluvastatin | Intervention Type: DRUG; Name: standard therapy; Assigned to Arm(s): standard therapy
D: Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementation and Evaluation of a Medical Reconciliation Protocol
Brief Summary: An incomplete understanding of patients' preadmission medications and failure to reconcile these with medications ordered in the hospital and at discharge are major, previously unappreciated, causes of adverse drug events (ADEs). The Joint Commission for Accreditation of Healthcare Organizations has now mandated a process for reconciling all medications at hospital admission and discharge. The best ways to implement medication reconciliation and the impact on patient outcomes are unknown. We, the researchers at at Brigham and Women's Hospital, will design and implement a medication reconciliation process with two major components: 1) information technology to integrate medication reconciliation into the current workflow at Brigham and Women's Hospital (BWH); and 2) process re-design involving physicians, nurses, and pharmacists to ensure that reconciliation takes place. We will then conduct a randomized controlled trial on the General Medical Service of BWH to evaluate the effects of this new process on reducing medication reconciliation errors with the potential to cause patient harm (potential ADEs).


Options:
A: Arm Label: Before collarborative pharmaceutical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: After collarborative pharmaceutical care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Pharmaceutical Care | Intervention Type: OTHER; Name: Collaborative Pharmaceutical Care; Assigned to Arm(s): After collarborative pharmaceutical care
B: Intervention Type: BEHAVIORAL; Name: Integration of a team based clinical pharmacist; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Optimizing therapeutic treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Optimizing processes of care; Assigned to Arm(s): N/A
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: New technology - PAML | Intervention Type: PROCEDURE; Name: New technology - PAML; Assigned to Arm(s): Intervention
D: Arm Label: Patients without intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinical pharmacy model | Arm Label: Patients with intervention; Type: EXPERIMENTAL; Interventions: Other: Clinical pharmacy model | Intervention Type: OTHER; Name: Clinical pharmacy model; Assigned to Arm(s): Patients with intervention, Patients without intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementation and Evaluation of a Medical Reconciliation Protocol
Brief Summary: An incomplete understanding of patients' preadmission medications and failure to reconcile these with medications ordered in the hospital and at discharge are major, previously unappreciated, causes of adverse drug events (ADEs). The Joint Commission for Accreditation of Healthcare Organizations has now mandated a process for reconciling all medications at hospital admission and discharge. The best ways to implement medication reconciliation and the impact on patient outcomes are unknown. We, the researchers at at Brigham and Women's Hospital, will design and implement a medication reconciliation process with two major components: 1) information technology to integrate medication reconciliation into the current workflow at Brigham and Women's Hospital (BWH); and 2) process re-design involving physicians, nurses, and pharmacists to ensure that reconciliation takes place. We will then conduct a randomized controlled trial on the General Medical Service of BWH to evaluate the effects of this new process on reducing medication reconciliation errors with the potential to cause patient harm (potential ADEs).


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pharmacist obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacist obtains admission medication history | Arm Label: Pharm tech obtains home med hx; Type: EXPERIMENTAL; Interventions: Other: Pharmacy technician obtains admission medication history | Intervention Type: OTHER; Name: Pharmacist obtains admission medication history; Assigned to Arm(s): Pharmacist obtains home med hx | Intervention Type: OTHER; Name: Pharmacy technician obtains admission medication history; Assigned to Arm(s): Pharm tech obtains home med hx
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: New technology - PAML | Intervention Type: PROCEDURE; Name: New technology - PAML; Assigned to Arm(s): Intervention
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease | Intervention Type: BEHAVIORAL; Name: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID
Brief Summary: This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: fluticasone propionate/salmeterol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): N/A
C: Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Montelukast Placebo | Intervention Type: DRUG; Name: Montelukast Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Salmeterol, Montelukast; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID
Brief Summary: This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.


Options:
A: Intervention Type: DRUG; Name: fluticasone propionate/salmeterol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tobacco Dependence: Treatment and Outcomes; Pharmacotherapies: Effectiveness in Primary Care
Brief Summary: The information gathered in this study may help to develop more effective ways to help people quit smoking and stay quit in the future.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Arm Label: nicotine lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine lozenge | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: patch + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: patch + lozenge | Arm Label: buproion + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + lozenge | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): nicotine lozenge | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: patch + lozenge; Assigned to Arm(s): patch + lozenge | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): buproion + lozenge
C: Arm Label: Bupropion and Weight Concerns intervention; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: weight concerns intervention | Arm Label: Placebo and Weight Concerns; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: weight concerns intervention | Arm Label: Bupropion and standard smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion, Behavioral: smoking cessation intervention | Arm Label: Placebo and standard smoking cessation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: smoking cessation intervention | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Bupropion and standard smoking cessation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Weight Concerns, Placebo and standard smoking cessation | Intervention Type: BEHAVIORAL; Name: weight concerns intervention; Assigned to Arm(s): Bupropion and Weight Concerns intervention, Placebo and Weight Concerns | Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): Bupropion and standard smoking cessation, Placebo and standard smoking cessation
D: Arm Label: INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean diet counseling | Arm Label: CONTROL GROUP: WITHOUT CHANGES IN DIET; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mediterranean diet counseling; Assigned to Arm(s): INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tobacco Dependence: Treatment and Outcomes; Pharmacotherapies: Effectiveness in Primary Care
Brief Summary: The information gathered in this study may help to develop more effective ways to help people quit smoking and stay quit in the future.


Options:
A: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A | Arm Label: 3; Type: N/A; Interventions: N/A | Arm Label: 4; Type: N/A; Interventions: N/A | Arm Label: 5; Type: N/A; Interventions: N/A | Arm Label: 6; Type: N/A; Interventions: N/A
B: Arm Label: High reinforcement cessation program; Type: EXPERIMENTAL; Interventions: Behavioral: high reinforcement cessation program | Arm Label: Low reinforcement cessation program; Type: EXPERIMENTAL; Interventions: Behavioral: low reinforcement cessation program | Intervention Type: BEHAVIORAL; Name: high reinforcement cessation program; Assigned to Arm(s): High reinforcement cessation program | Intervention Type: BEHAVIORAL; Name: low reinforcement cessation program; Assigned to Arm(s): Low reinforcement cessation program
C: Arm Label: PRO+NRT+TC; Type: EXPERIMENTAL; Interventions: Other: proactive outreach (PRO), Other: telephone counseling (TC), Other: Nicotine replacement therapy (NRT) | Arm Label: Usual Care (UC); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care (UC) | Intervention Type: OTHER; Name: proactive outreach (PRO); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: telephone counseling (TC); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Nicotine replacement therapy (NRT); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Usual care (UC); Assigned to Arm(s): Usual Care (UC)
D: Arm Label: patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Arm Label: nicotine lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine lozenge | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: patch + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: patch + lozenge | Arm Label: buproion + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + lozenge | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): nicotine lozenge | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: patch + lozenge; Assigned to Arm(s): patch + lozenge | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): buproion + lozenge

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tobacco Dependence: Treatment and Outcomes; Pharmacotherapies: Effectiveness in Primary Care
Brief Summary: The information gathered in this study may help to develop more effective ways to help people quit smoking and stay quit in the future.


Options:
A: Arm Label: Nicotine Patch (4 weeks); Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Nicotine Patch (8 weeks); Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch (4 weeks), Nicotine Patch (8 weeks)
B: Arm Label: patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Arm Label: nicotine lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine lozenge | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: patch + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: patch + lozenge | Arm Label: buproion + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + lozenge | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): nicotine lozenge | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: patch + lozenge; Assigned to Arm(s): patch + lozenge | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): buproion + lozenge
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Placebo, Varenicline
D: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management

Answer: B